6 recruiting, 3 completed, 3 terminated, 2 active not recruiting. 11 Phase 2, 4 Phase 1, 4 Phase 3.
Follow TAS-120: new trials by email Literature Review of TAS-120 trials Research Report on TAS-120
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, OPTIC Trial Biospecimen Collection, Cisplatin, Computed Tomography - Resectable Intrahepatic Cholangiocarcinoma | Phase 2 | Not yet recruiting | Northwestern University | 44 | 2027-12-10 | 2026-06-10 |
| Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Biospecimen Collection, Computed Tomography, Futibatinib - Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Phase 1 | Not yet recruiting | Northwestern University | 18 | 2027-09-09 | 2026-10-20 |
| Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer Futibatinib, Zimberelimab, Durvalumab - Biliary Tract Cancer | Phase 3 | Recruiting | Taiho Pharmaceutical Co., Ltd. | 784 | 2026-06-24 | 2026-07-17 |
| Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy Biospecimen Collection, Computed Tomography, Durvalumab - Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma | Phase 2 | Recruiting | Yuanquan Yang | 24 | 2024-12-30 | 2026-10-01 |
| Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. futibatinib, futibatinib, fulvestrant - Advanced/Metastatic Cancer | Phase 2 / Phase 3 | Active not recruiting | Taiho Oncology, Inc. | 15 | 2024-10-01 | 2026-07-28 |
| Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors Futibatinib, Pembrolizumab, Cisplatin - Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma | Phase 2 | Active not recruiting | Taiho Oncology, Inc. | 53 | 2023-07-13 | 2026-09-01 |
| Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement TAS-120 - Advanced Cholangiocarcinoma, FGFR2 Fusions | Phase 2 | Recruiting | Taiho Oncology, Inc. | 120 | 2023-07-05 | 2026-09-01 |
| Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer Futibatinib, Pembrolizumab, Quality-of-Life Assessment - Advanced Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma | Phase 2 | Completed | Mayo Clinic | 14 | 2021-08-17 | 2025-11-18 |
| AB122 Platform Study AB122, TAS-116, TAS-120 - Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma | Phase 1 | Recruiting | Taiho Pharmaceutical Co., Ltd. | 917 | 2021-06-01 | 2026-08-05 |
| Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements Futibatinib, Cisplatin, Gemcitabine - Advanced Cholangiocarcinoma, FGFR2 Gene Rearrangements | Phase 3 | Terminated | Taiho Oncology, Inc. | 10 | 2021-01-06 | 2025-02-07 |
| Futibatinib in Patients With Specific FGFR Aberrations Futibatinib - Advanced or Metastatic Solid Tumor, Advanced or Metastatic Gastric or Gastroesophageal Cancer | Phase 2 | Terminated | Taiho Oncology, Inc. | 115 | 2020-08-05 | 2025-10-08 |
| A Study of TAS-120 in Patients With Metastatic Breast Cancer Futibatinib, Futibatinib plus Fulvestrant - Metastatic Breast Cancer, FGFR 1 High Amplification | Phase 2 | Terminated | Taiho Oncology, Inc. | 64 | 2020-01-28 | 2025-11-13 |
| Molecular Profiling of Advanced Soft-tissue Sarcomas Nilotinib, Ceritinib, Capmatinib - Soft Tissue Sarcoma | Phase 3 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 603 | 2019-10-19 | 2026-04-29 |
| A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) Atezolizumab, Futibatinib, Amivantamab - Advanced Solid Tumor | Phase 2 | Recruiting | Vall d'Hebron Institute of Oncology | 1000 | 2018-12-10 | 2024-04-25 |
| European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors Ribociclib, Topotecan, Temozolomide - Pediatric Cancer | Phase 1 / Phase 2 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 472 | 2016-08-03 | 2026-07-10 |
| A Study of TAS-120 in Patients With Advanced Solid Tumors Futibatinib - Cholangiocarcinoma, Urothelial Cancer | Phase 1 / Phase 2 | Completed | Taiho Oncology, Inc. | 407 | 2014-07-21 | 2025-03-27 |
| Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements TAS-120 - Advanced Cholangiocarcinoma | Approved for marketing | Taiho Oncology, Inc. | 2026-03-10 |
Cholangiocarcinoma (4) · Neoplasm Metastasis (4) · Stomach Neoplasms (3) · Adenocarcinoma Of Esophagus (2) · Biliary Tract Neoplasms (2) · Breast Neoplasms (2) · Esophageal Neoplasms (2) · Neoplasms (2) · Acrocephalosyndactylia (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Head and Neck Neoplasms (1) · Pancreatic Neoplasms (1)
Taiho Oncology, Inc. (8) · Northwestern University (2) · Taiho Pharmaceutical Co., Ltd. (2) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · Mayo Clinic (1) · Vall d'Hebron Institute of Oncology (1) · Yuanquan Yang (1)
United States (12) · France (9) · Spain (9) · Italy (7) · United Kingdom (7) · Japan (6) · South Korea (6) · Germany (5) · Netherlands (5) · Australia (4) · Hong Kong (4) · Portugal (4) · Canada (3) · Argentina (2) · Belgium (2)
Antoine Italiano (1) · Birgit Geoerger, MD (1) · Gladys Rodriguez, MD (1) · Jordi Rodon, MD (1) · Nguyen H. Tran, M.D. (1) · Shishir K Maithel, MD (1) · Yuanquan Yang, MD, PhD (1)
PMID 31538815, PMID 32622884, PMID 32713836, PMID 33892407, PMID 34347542, PMID 34543871, PMID 34740331, PMID 35292802, PMID 36652354, PMID 37972659, PMID 38884254, PMID 41838385, PMID 42686334
2019 (3), 2017 (2), P30CA060553 (2), 2016 (1), 2023 (1)